| Study Period | 2019 - 2030 |
| 乐鱼体育官网 Size (2025) | USD 171.66 Million |
| 乐鱼体育官网 Size (2030) | USD 231.90 Million |
| CAGR (2025 - 2030) | 6.20 % |
| Fastest Growing 乐鱼体育官网 | North America |
| Largest 乐鱼体育官网 | Asia Pacific |
| 乐鱼体育官网 Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Lentiviral Vector Contract Development And Manufacturing Organizations 乐鱼体育官网 Analysis
The Lentiviral Vector Contract Development And Manufacturing Organizations 乐鱼体育官网 size is estimated at USD 171.66 million in 2025, and is expected to reach USD 231.90 million by 2030, at a CAGR of 6.2% during the forecast period (2025-2030).
Cell and gene therapy's growing emphasis and development are expected to contribute to the lentiviral vector CDMO 乐鱼体育官网 growth. Cell and gene therapies have demonstrated remarkable success in treating previously untreatable or difficult-to-treat diseases, including certain types of cancer, genetic disorders, and autoimmune conditions. For instance, in September 2023, BioViros, a full-service CDMO specializing in lentiviral vectors for cell and gene therapy, announced the opening of its state-of-the-art laboratory for lentiviral vectors in New Zealand. Additionally, in January 2023, Vector BioMed has innovated a technological platform for designing and producing lentiviruses utilized in cell and gene therapy delivery.
Moreover, increasing fundraising activities by the 乐鱼体育官网 players to expand the CDMO services is likely to contribute to the 乐鱼体育官网 growth. For instance, in January 2023, iVexSol Inc., a CDMO, announced USD 23.8 million in Series A-3 funding. The new funding will be used to invest in iVexSol鈥檚 Intelligent Vector Solutions by advancing process and analytical technologies, expanding technical teams in Quality, Regulatory, and cGMP operations, and augmenting existing infrastructure to support the production of stable lentiviral vector (LVV) producer cell lines.
Similarly, in January 2023, Vector BioMed commenced operations as a CDMO, receiving financial backing from Viking Global Investors and Casdin Capital's seed round. These funds will facilitate the scaling of commercial operations, enabling prompt delivery of premium lentiviral vectors for preclinical research, clinical trials, and commercial use. Vector BioMed specializes in providing solutions that empower partners to advance their lentiviral vector-based treatments into clinical trials, thereby expediting their journey to commercialization.
The heightened focus on cell and gene therapy and the surge in investment in lentiviral vector-based therapeutics, coupled with 乐鱼体育官网 players' strategic initiatives, are projected to propel 乐鱼体育官网 growth.Nevertheless, the limitations in scalability and the challenges with downstream purification are anticipated to limit 乐鱼体育官网 expansion during the forecast period.
Lentiviral Vector Contract Development And Manufacturing Organizations 乐鱼体育官网 Trends
Cancer is Expected to Hold a Major Share in the Studied 乐鱼体育官网 Over The Forecast Period.
Lentiviral vectors are a type of modified virus commonly used in gene therapy for cancer treatment. CDMOs are responsible for the design, development, and optimization of lentiviral vectors tailored for specific cancer therapies. This involves engineering vectors to efficiently deliver therapeutic genes to target cancer cells.
The increasing prevalence of cancer is drive the demand for advanced and effective therapeutics, leading to new investments by companies and other stakeholders, like governments, for the identification, testing, and development of novel cancer therapeutics. For instance, according to the Canadian Cancer Statistics 2023 report, about 239.2 thousand new cancer cases were reported in 2023 in Canada, compared to 233.9 thousand in 2022. Thus, the growing burden of cancer is expected to create the demand for drug development and manufacturing services which is likely to contribute to segment growth.
The increasing research & development activities and collaboration with CDMO providers to effectively complete the drug development process using lentiviral vectors are expected to contribute to segment growth. For instance, in March 2023, Eutilex, a partner of GenScript ProBio, a CDMO announced that Ministry of Food and Drug Safety (MFDS) clearance of its hepatocellular carcinoma clinical trial application for innovative CAR-T program (EU307). GenScript ProBio provided integrated plasmid and lentiviral vector CMC service to Eutilex and helped with the CTD document writing for MFDS IND filing.
Hence, increasing research and development activities involving lentiviral vectors are expected to create demand for CDMO services over the forecast period.
Understand The Key Trends Shaping This 乐鱼体育官网
Download PDF
North America is Expected to Hold a Significant 乐鱼体育官网 Share Over the Forecast Period
The North American region is expected to dominate the 乐鱼体育官网 over the forecast period due to increasing research advancements in gene therapy, rising research for the development of new vaccines using lentivirus, and the presence of major 乐鱼体育官网 players offering lentiviral vector contract development and manufacturing services in the region.
North America is a hub for cutting-edge research in gene therapy and region is home to numerous academic institutions, biotech companies, and research organizations that are actively engaged in developing innovative gene-based treatments. For instance, in September 2022, Charles River a CDMO reported that the lentiviral vector platform enables a cost-effective and reliable path to GMP in less than seven months. Lentivation integrates the three pillars of plasmid DNA, lentiviral vector production, and testing, to provide LVV-based gene therapy and gene-modified cell therapy . Hence, the adoption of these services is expected to increase due to the benefits offered by the services, thereby boosting 乐鱼体育官网 growth.
Companies in North America often engage in collaborations and partnerships with academic institutions, research organizations, and other industry players. These collaborations facilitate knowledge exchange, give access to cutting-edge technologies, and pooling of resources for research and development. For instance, in September 2023, Kyverna Therapeutics announced a non-exclusive, multi-year license and supply agreement with Oxford Biomedica plc, a quality and innovation-led viral vector CDMO, enabling the use of LentiVector with any Kyverna product.
Hence, growing interest in cell and gene therapy, substantial investment, and strategic collaborations and partnerships are expected to boost the 乐鱼体育官网 in the North American region over the forecast period.
Get Analysis on Important Geographic 乐鱼体育官网s
Download PDF
Lentiviral Vector Contract Development And Manufacturing Organizations Industry Overview
The lentiviral vector contract development and manufacturing organization 乐鱼体育官网 is fragmented in nature with the presence of many 乐鱼体育官网 players. They are continuously engaged in research and development activities, along with collaborations, partnerships, and facility expansion. Some of the key players in the lentiviral vector CDMO 乐鱼体育官网 are Thermo Fischer Scientific, Inc., Oxford Biomedica, Charles River Laboratories International, Inc., GenScript ProBio, Catalent Inc..and among other
Lentiviral Vector Contract Development And Manufacturing Organizations 乐鱼体育官网 Leaders
-
Thermo Fischer Scientific, Inc
-
Oxford Biomedica
-
Charles River Laboratories International, Inc.
-
GenScript ProBio
-
Catalent Inc.
- *Disclaimer: Major Players sorted in no particular order
Need More Details on 乐鱼体育官网 Players and Competiters?
Download PDF
Lentiviral Vector Contract Development And Manufacturing Organizations 乐鱼体育官网 News
- In February 2024, Genezen the Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) has inked a licensing pact with CSL to acquire their exclusive Cytegrity stable production system. This collaboration intends to amplify the manufacturing of lentiviral vectors (LVVs), enabling cost-efficient and scalable production.
- In September 2023, Charles River Laboratories International, Inc. introduced its new Lentivation Lentiviral Vector (LVV) manufacturing platform. This platform is capable of reducing LVV manufacturing timelines for gene and gene-modified cell therapies by up to 60%, resulting in a timeframe of less than seven months compared to traditional manufacturing workflows.
Lentiviral Vector Contract Development And Manufacturing Organizations Industry Segmentation
As per the scope of the report, the lentiviral vector CDMO 乐鱼体育官网 refers to the industry segment that specializes in providing services related to the development and manufacturing of lentiviral vectors for various applications, particularly in the field of gene therapy. Lentiviral vector contract development and manufacturing organizations 乐鱼体育官网 is segmented by component, disease indication, end user, and geography. By component, the 乐鱼体育官网 is segmented as lentiviral promoter, lentiviral fusion tags, lentivirus packaging systems, and other components. By disease indication, the 乐鱼体育官网 is segmented as cancer, genetic disorders, infectious diseases, veterinary diseases, and other disease indications. By end user, the 乐鱼体育官网 is segmented as pharmaceutical and biotech, academic research, and other end users. By geography, the 乐鱼体育官网 is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated 乐鱼体育官网 sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.
| By Component | Lentiviral Promoter | ||
| Lentiviral Fusion Tags | |||
| Lentivirus Packaging Systems | |||
| Other Components | |||
| By Disease Indication | Cancer | ||
| Genetic Disorders | |||
| Infectious Diseases | |||
| Veterinary Disease | |||
| Other Disease Indication | |||
| By End User | Pharmaceutical and Biotechnology Company | ||
| Academic Research | |||
| Other End Users | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | United Kingdom | ||
| Germany | |||
| France | |||
| Spain | |||
| Italy | |||
| Rest of Europe | |||
| Asia Pacific | India | ||
| Japan | |||
| China | |||
| Australia | |||
| South Korea | |||
| Rest of Asia Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of the Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Lentiviral Vector Contract Development And Manufacturing Organizations 乐鱼体育官网 Research FAQs
How big is the Lentiviral Vector Contract Development And Manufacturing Organizations 乐鱼体育官网?
The Lentiviral Vector Contract Development And Manufacturing Organizations 乐鱼体育官网 size is expected to reach USD 171.66 million in 2025 and grow at a CAGR of 6.20% to reach USD 231.90 million by 2030.
What is the current Lentiviral Vector Contract Development And Manufacturing Organizations 乐鱼体育官网 size?
In 2025, the Lentiviral Vector Contract Development And Manufacturing Organizations 乐鱼体育官网 size is expected to reach USD 171.66 million.
Who are the key players in Lentiviral Vector Contract Development And Manufacturing Organizations 乐鱼体育官网?
Thermo Fischer Scientific, Inc, Oxford Biomedica, Charles River Laboratories International, Inc., GenScript ProBio and Catalent Inc. are the major companies operating in the Lentiviral Vector Contract Development And Manufacturing Organizations 乐鱼体育官网.
Which is the fastest growing region in Lentiviral Vector Contract Development And Manufacturing Organizations 乐鱼体育官网?
North America is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Lentiviral Vector Contract Development And Manufacturing Organizations 乐鱼体育官网?
In 2025, the Asia Pacific accounts for the largest 乐鱼体育官网 share in Lentiviral Vector Contract Development And Manufacturing Organizations 乐鱼体育官网.
What years does this Lentiviral Vector Contract Development And Manufacturing Organizations 乐鱼体育官网 cover, and what was the 乐鱼体育官网 size in 2024?
In 2024, the Lentiviral Vector Contract Development And Manufacturing Organizations 乐鱼体育官网 size was estimated at USD 161.02 million. The report covers the Lentiviral Vector Contract Development And Manufacturing Organizations 乐鱼体育官网 historical 乐鱼体育官网 size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Lentiviral Vector Contract Development And Manufacturing Organizations 乐鱼体育官网 size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Lentiviral Vector Contract Development And Manufacturing Organizations Industry Report
Statistics for the 2025 Lentiviral Vector Contract Development And Manufacturing Organizations 乐鱼体育官网 share, size and revenue growth rate, created by Mordor Intelligence鈩� Industry Reports. Lentiviral Vector Contract Development And Manufacturing Organizations analysis includes a 乐鱼体育官网 forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
